Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwired) -- 01/11/17 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced that the first patient has been dosed for the second cohort of its clinical trial program for IMP321 in combination with KEYTRUDA® being conducted in Australia. The second cohort will recruit up to six patients with unresectable or metastatic melanoma that have had a suboptimal response to KEYTRUDA.
Interim data from the first patient cohort released in December 2016 indicate IMP321 is safe and well tolerated. On the basis of this safety data, the Data Safety Monitoring Board (DSMB) gave approval for the second cohort to commence.
TACTI-mel (Two ACTive Immunotherapeutics in melanoma) is a multicentre, open label, Phase I study in which patients with unresectable or metastatic melanoma will be dosed with IMP321 in combination with the PD-1 checkpoint inhibitor pembrolizumab (KEYTRUDA). The study will evaluate safety as the primary endpoint and anti-tumour activity and the immune response to the combination as secondary endpoints.
IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient's own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response.
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit .
Matthew Beck
The Trout Group LLC
+1 (646) 378-2933
Mr Matthew Gregorowski
Citadel-MAGNUS
+61 2 8234 0105
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.01.2017 - 23:41 Uhr
Sprache: Deutsch
News-ID 517109
Anzahl Zeichen: 0
contact information:
Town:
SYDNEY, AUSTRALIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 346 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial"
steht unter der journalistisch-redaktionellen Verantwortung von
PRIMA BIOMED LTD (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
